VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $5.75 price objective on the stock. HC Wainwright’s target price points to a potential upside of 162.56% from the stock’s current price.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Stock Performance

VYNE opened at $2.19 on Thursday. The business’s 50-day simple moving average is $2.76 and its 200-day simple moving average is $2.50. VYNE Therapeutics has a one year low of $1.57 and a one year high of $4.30. The stock has a market capitalization of $32.30 million, a P/E ratio of -2.55 and a beta of 1.13.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.14 million. On average, equities research analysts forecast that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Insider Buying and Selling at VYNE Therapeutics

In related news, Director Patrick G. Lepore bought 15,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the purchase, the director now owns 51,472 shares in the company, valued at $150,298.24. This trade represents a 41.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On VYNE Therapeutics

Several large investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of VYNE Therapeutics in the fourth quarter valued at approximately $68,000. XTX Topco Ltd purchased a new stake in VYNE Therapeutics in the 4th quarter worth approximately $70,000. Bridgeway Capital Management LLC bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at $124,000. Adage Capital Partners GP L.L.C. bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at $516,000. Finally, Schonfeld Strategic Advisors LLC grew its stake in VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares during the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.